The Role of MDM2 In Neuroendocrine Tumors: A Novel Therapeutic Target

Volume 5 - Issue 4

Reddy Priyanka and Amr Mohamed*

Received: August 04, 2020;   Published: August 21, 2020

DOI: 10.32474/RRHOAJ.2020.05.000217

Full Text PDF

To view the Full Article   Peer-reviewed Article PDF

Abstract

Neuroendocrine tumors (NETs) are neoplasms derived from neuroendocrine cells which secrete hormones that cause distinct clinical syndromes. They are considered rare tumors, but annual incidence has increased significantly with recent SEER analysis showing a 6.4-fold increased incidence from 1973 (1.09 per 100,000) to 2012 (6.98 per 100,000) [1]. They are highly diverse neoplasms that can be divided into several subgroups based on embryonic derivation, histology, functionality, and origin of primary tumor. One of the most important classifications, based on histologic differentiation and grade, divides NETs into well-differentiated and poorly differentiated neoplasms [2]. Well-differentiated NETs are indolent tumors with a slow progression profile, while poorly differentiated neuroendocrine carcinomas (NECs) are aggressive tumors with worse outcomes [3]. Well-differentiated and poorly differentiated tumors have vastly different responses to treatment and thus require different clinical approaches [2].

Introduction| TP53 and MDM2| IntrRole of P53 and MDM2 in different groups of neuroendocrine tumorsoduction| Targeting MDM2| Conclusion| References|